[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jordan Collaborating Cardiology Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":171},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,72,96,115,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618148","how-often-does-the-fecal-test-for-occult-blood-turn-positive-after-using-blood-thinners-100618148",false,"NCT07327853","How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?","Exploring the Prevalence and Potential Benefits of Fecal Immunochemical Test Before Ana After Use of Antiplatelet and Anticoagulant Agents","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Have an indication to use oral antiplatelet or anticoagulant agent(s).\n* Absence of past bleeding tendency of gastrointestinal disease.\n* Agrees to have the test done (FIT).\n* Agrees to sign the informed consent.\n\nExclusion Criteria:\n\n* Presence of past bleeding tendency of gastrointestinal disease.\n* Refusal to have the test done (FIT).\n* Refusal to sign the informed consent.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover serious disease in the stomach and intestine and enable the treating physician to refer the patient for further evaluation.",[24,25,26],"Gastrointestinal Bleeding","Antiplatelet Agents","Oral Anticoagulant Therapy",[28,29,30,31,32,33],"Occult fecal blood","Fecal Immunochemical Test (FIT)","Gastrointestinal bleeding","Antiplatelet agents","Oral anticoagulant agents","Cardiovascular disease","NOT_YET_RECRUITING","2025-12-25",{"date":37,"type":38},"2026-01-08","ACTUAL",{"date":40,"type":20},"2026-02-01",{"date":42,"type":20},"2027-04-30",{"name":44,"class":45},"Jordan Collaborating Cardiology Group","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100615904","cardiovascular-risk-factors-in-middle-eastern-patients-with-stroke-100615904","NCT07298668","Cardiovascular Risk Factors in Middle Eastern Patients With Stroke","Standard Modifiable Risk Factors in Middle Eastern Patients With Stroke (Jo-SMMART Study)","JoSMMART","Inclusion Criteria:\n\n* Diagnosis of stroke upon admission to the hospital\n* Adult aged 18 years or older\n* Available lipid profile on hospital admission\n\nExclusion Criteria:\n\n* Stroke diagnosis unconfirmed\n* age younger than 18 years\n* No available lipid profile on admission",{"count":56,"type":20},2000,"Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.",[59,60,61],"Stroke","Low-Density-Lipoprotein-cholesterol Level","Risk Factors",[59,63],"Risk factors","2025-12-22",{"date":66,"type":38},"2025-12-23",{"date":68,"type":20},"2025-12-31",{"date":70,"type":20},"2027-01-31",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100614106","incidental-findings-on-coronary-computed-tomography-angiography-100614106","NCT07275281","Incidental Findings on Coronary Computed Tomography Angiography","Incidental Noncardiac Findings on Coronary Computed Tomography Angiography","Inclusion Criteria:\n\n* Adult patients ho underwent CCTA\n\nExclusion Criteria:\n\n* None",{"count":56,"type":20},"Coronary CT angiography (CCTA) is increasingly used for ischemic heart disease diagnosis. The rising number of CCTA tests has led to a significant increase in the number of finding unexpected incidental extracardiac diseases.",[82,83,84],"Computed Tomography","Coronary Angiography","Incidental Findings",[86,87,88],"Coronary artery disease","computed tomography","indidental findings",{"date":90,"type":38},"2025-12-30",{"date":92,"type":20},"2026-01-02",{"date":94,"type":20},"2027-02-28",{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100547837","the-cardiovascular-renal-metabolic-crm-syndrome-survey-in-jordan-100547837","NCT06413160","The Cardiovascular-Renal-Metabolic (CRM) Syndrome Survey in Jordan","JoCRMSSurvey","Inclusion Criteria:\n\n* Adults (age 18 years and above).\n* Willing to sign an informed consent.\n\nExclusion Criteria:\n\n* None.",true,{"count":105,"type":20},10000,"Cardiovascular-renal-metabolic (CRM) syndrome is defined as a systemic disorder with a collection of related signs and symptoms attributable to the coexistence of multiple cardiovascular, renal and metabolic disease with a common underlying pathophysiology in one individual. Surveying this syndrome in a large population in Jordan aims at studying the risk factors, components and stages of the syndrome, thus helping early screening, diagnosing and treating disease and its risk factors.",[108],"Cardiovascular-renal-metabolic Syndrome",{"date":90,"type":38},{"date":111,"type":20},"2026-07-01",{"date":113,"type":20},"2027-12-31",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":124,"studyType":21,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100595953","pretreatment-of-acute-coronary-syndrome-with-dual-antiplatelet-agents-100595953","NCT07039149","Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents","Dual Antiplatelet Agents Therapy in the Emergency Department for Acute Coronary Syndrome (The DATES Study).","DATES","Inclusion Criteria:\n\n* Adult patients\n* Presenting with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina).\n* Antiplatelet medication (s) prescribed during index admission to hospital.\n* Willingness of the patient to be called for follow up up to 1 year after index hospitalization.\n\nExclusion Criteria:\n\n* Non cardiac chest pain.\n* No administration of antiplatelet agents during hospitalization.\n* Refusal of contact for follow up.",{"count":19,"type":20},"1 Year","This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?",[127,128],"Major Bleeding","Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)",[130,131,132],"Dual antiplatelet therapy","Pretreatment with DAPT","Acute coronary syndrome","RECRUITING","2025-11-26",{"date":136,"type":38},"2025-11-28",{"date":138,"type":38},"2025-08-01",{"date":140,"type":20},"2026-11-01",{"name":44,"class":45},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":158,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":46},"100541588","clinical-association-between-obstructive-sleep-apnea-facial-pigmentation-and-vasovagal-symptoms-100541588","NCT06331819","Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms.","Clinical Association Between Obstructive Sleep Apnea (OSA) and Facial Pigmentation, and the Relation Between OSA and Vasovagal Symptoms With Resulting Smoking Tendency and the Effect of Treatment in Patients Referred for Sleep Study.","VasOSA","Inclusion Criteria:\n\n* Patients within age limit who agree to participate and sign the consent form.\n\nExclusion Criteria:\n\n* Patients with prior diagnosis of obstructive sleep apnea by sleep study.",{"count":19,"type":20},"The goal of this prospective cohort study is to study patients referred for sleep study by in-lab polysomnography in the Jordan University Hospital and the Jordan Hospital or with an at-home sleep study kit. The main aims are:\n\n* To prospectively obtain demographic and clinical information of patients referred for a sleep study.\n* To determine the diagnostic value of facial discoloration as potential marker for obstructive sleep apnea to increase detection rate for the condition.\n* To establish a correlation between obstructive sleep apnea and vasovagal symptoms with resulting increased smoking tendency and study the effect of treatment on the disorders.\n* To determine the association between timing of appearance of obstructive sleep apnea symptoms and initiation of smoking.",[154,155,156,157],"Obstructive Sleep Apnea","Vasovagal Syncope","Smoking","Acanthosis Nigricans",[154,155,159,157,160,161,162],"Facial Discoloration","Smoking Cessation","Jordan","In-Lab Polysomnography","2024-09-07",{"date":165,"type":38},"2024-09-19",{"date":167,"type":38},"2024-03-10",{"date":169,"type":20},"2026-03-01",{"name":44,"class":45},""]